Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Kidney Fibrosis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H1 2017, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape. Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 4, 25 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively. Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones). - The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Kidney Fibrosis - Overview Kidney Fibrosis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Kidney Fibrosis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Kidney Fibrosis - Companies Involved in Therapeutics Development AbbVie Inc Allergan Plc Angion Biomedica Corp Apollo Endosurgery Inc BiOrion Technologies BV Cellmid Ltd Epigen Biosciences Inc Evotec AG Galectin Therapeutics Inc GenKyoTex SA Horizon Pharma Plc Intercept Pharmaceuticals Inc Isarna Therapeutics GmbH MorphoSys AG Pharmaxis Ltd ProMetic Life Sciences Inc Regulus Therapeutics Inc Sirnaomics Inc Symic Biomedical Inc Vascular Biogenics Ltd Kidney Fibrosis - Drug Profiles ANG-3070 - Drug Profile Product Description Mechanism Of Action R&D Progress ANG-3586 - Drug Profile Product Description Mechanism Of Action R&D Progress ANG-4021 - Drug Profile Product Description Mechanism Of Action R&D Progress BOT-191 - Drug Profile Product Description Mechanism Of Action R&D Progress CAB-102 - Drug Profile Product Description Mechanism Of Action R&D Progress cenicriviroc mesylate - Drug Profile Product Description Mechanism Of Action R&D Progress CT-140 - Drug Profile Product Description Mechanism Of Action R&D Progress cysteamine DR - Drug Profile Product Description Mechanism Of Action R&D Progress Drug to Inhibit Galectin-3 for Liver Fibrosis, Pulmonary Fibrosis and Kidney Fibrosis - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs for Tissue Fibrosis - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile Product Description Mechanism Of Action R&D Progress GKT-136901 - Drug Profile Product Description Mechanism Of Action R&D Progress GRMD-02 - Drug Profile Product Description Mechanism Of Action R&D Progress ICG-001 - Drug Profile Product Description Mechanism Of Action R&D Progress INT-767 - Drug Profile Product Description Mechanism Of Action R&D Progress IP-9 - Drug Profile Product Description Mechanism Of Action R&D Progress ISTH-0047 - Drug Profile Product Description Mechanism Of Action R&D Progress LJ-1888 - Drug Profile Product Description Mechanism Of Action R&D Progress Lpathomab - Drug Profile Product Description Mechanism Of Action R&D Progress melittin - Drug Profile Product Description Mechanism Of Action R&D Progress MOR-107 - Drug Profile Product Description Mechanism Of Action R&D Progress P-007 - Drug Profile Product Description Mechanism Of Action R&D Progress PBI-4050 - Drug Profile Product Description Mechanism Of Action R&D Progress PXS-4820 - Drug Profile Product Description Mechanism Of Action R&D Progress PXS-5033A - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile Product Description Mechanism Of Action R&D Progress RG-012 - Drug Profile Product Description Mechanism Of Action R&D Progress SB-300 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile Product Description Mechanism Of Action R&D Progress SOL-1 - Drug Profile Product Description Mechanism Of Action R&D Progress STP-705 - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile Product Description Mechanism Of Action R&D Progress TEW-7197 - Drug Profile Product Description Mechanism Of Action R&D Progress VB-201 - Drug Profile Product Description Mechanism Of Action R&D Progress VB-703 - Drug Profile Product Description Mechanism Of Action R&D Progress Wnt-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Kidney Fibrosis - Dormant Projects Kidney Fibrosis - Product Development Milestones Featured News & Press Releases Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02 Feb 21, 2017: MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107 Nov 18, 2016: ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015 Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Kidney Fibrosis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Kidney Fibrosis - Pipeline by AbbVie Inc, H1 2017 Kidney Fibrosis - Pipeline by Allergan Plc, H1 2017 Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H1 2017 Kidney Fibrosis - Pipeline by Apollo Endosurgery Inc, H1 2017 Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H1 2017 Kidney Fibrosis - Pipeline by Cellmid Ltd, H1 2017 Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H1 2017 Kidney Fibrosis - Pipeline by Evotec AG, H1 2017 Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2017 Kidney Fibrosis - Pipeline by GenKyoTex SA, H1 2017 Kidney Fibrosis - Pipeline by Horizon Pharma Plc, H1 2017 Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals Inc, H1 2017 Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2017 Kidney Fibrosis - Pipeline by MorphoSys AG, H1 2017 Kidney Fibrosis - Pipeline by Pharmaxis Ltd, H1 2017 Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2017 Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc, H1 2017 Kidney Fibrosis - Pipeline by Sirnaomics Inc, H1 2017 Kidney Fibrosis - Pipeline by Symic Biomedical Inc, H1 2017 Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, H1 2017 Kidney Fibrosis - Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
